SMS Lifesciences India Limited (SMSLIFE.BO)
INR 1350.85
(2.06%)
INR 1350.85
(2.06%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 349.41 Million INR | -1.09% |
| 2022 | 341.76 Million INR | -11.79% |
| 2021 | 489.1 Million INR | 12.93% |
| 2020 | 319.58 Million INR | 16.78% |
| 2019 | 276.66 Million INR | -25.2% |
| 2018 | 372.61 Million INR | 137.03% |
| 2017 | 162.69 Million INR | -47.62% |
| 2016 | 301.71 Million INR | 1573710.81% |
| 2015 | - INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 162.84 Million INR | 18.68% |
| 2023 Q3 | 98.74 Million INR | 20.42% |
| 2023 FY | - INR | -1.09% |
| 2023 Q2 | 81.99 Million INR | 160.76% |
| 2023 Q1 | 31.44 Million INR | -28.07% |
| 2023 Q4 | 113.59 Million INR | 15.04% |
| 2022 Q2 | 84.21 Million INR | -4.25% |
| 2022 Q3 | 98.66 Million INR | 17.16% |
| 2022 Q4 | 43.71 Million INR | -55.69% |
| 2022 Q1 | 87.95 Million INR | 2.16% |
| 2022 FY | - INR | -11.79% |
| 2021 Q4 | 86.09 Million INR | 1.35% |
| 2021 FY | - INR | 12.93% |
| 2021 Q2 | 102.79 Million INR | 24.22% |
| 2021 Q1 | 82.74 Million INR | -11.32% |
| 2021 Q3 | 84.94 Million INR | -17.36% |
| 2020 Q2 | 82.54 Million INR | 23.24% |
| 2020 FY | - INR | 16.78% |
| 2020 Q1 | 66.98 Million INR | 54.02% |
| 2020 Q3 | 73 Million INR | -11.56% |
| 2020 Q4 | 93.3 Million INR | 27.8% |
| 2019 Q2 | 92.49 Million INR | -11.09% |
| 2019 FY | - INR | -25.2% |
| 2019 Q4 | 43.48 Million INR | 45.26% |
| 2019 Q3 | 29.93 Million INR | -67.63% |
| 2019 Q1 | 104.03 Million INR | 11.51% |
| 2018 Q1 | 69.55 Million INR | 138.51% |
| 2018 FY | - INR | 137.03% |
| 2018 Q4 | 93.29 Million INR | -25.24% |
| 2018 Q3 | 124.8 Million INR | 41.35% |
| 2018 Q2 | 88.29 Million INR | 26.94% |
| 2017 Q3 | 55.6 Million INR | 62.57% |
| 2017 Q4 | 29.16 Million INR | -47.56% |
| 2017 FY | - INR | -47.62% |
| 2017 Q1 | 43.57 Million INR | -36.0% |
| 2017 Q2 | 34.2 Million INR | -21.5% |
| 2016 Q1 | 87.6 Million INR | 0.0% |
| 2016 Q3 | 89.62 Million INR | 59.45% |
| 2016 Q2 | 56.21 Million INR | -35.84% |
| 2016 FY | - INR | 1573710.81% |
| 2016 Q4 | 68.08 Million INR | -24.04% |
| 2015 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 10.12 Million INR | -3351.304% |
| Biocon Limited | 41.52 Billion INR | 99.159% |
| Blue Jet Healthcare Limited | 2.29 Billion INR | 84.757% |
| Concord Biotech Limited | 4.65 Billion INR | 92.501% |
| Dishman Carbogen Amcis Limited | 3.07 Billion INR | 88.625% |
| FERMENTA BIOTECH LIMITED | 262.68 Million INR | -33.016% |
| GENOMIC VALLEY BIOTECH LIMITED | 147.4 Thousand INR | -236945.63% |
| Lyka Labs Limited | 167.58 Million INR | -108.492% |
| Panacea Biotec Limited | -200.6 Million INR | 274.182% |
| SAMSRITA LABS LIMITED | -2.46 Million INR | 14301.061% |
| Servoteach Industries Limited | - INR | -Infinity% |
| Supriya Lifescience Limited | 1.83 Billion INR | 80.966% |
| Syngene International Limited | 10.84 Billion INR | 96.779% |
| TAKE Solutions Limited | -1.05 Billion INR | 133.251% |
| Titan Biotech Limited | 360.29 Million INR | 3.021% |
| Transgene Biotek Limited | -4.33 Million INR | 8152.777% |
| Vanta Bioscience Limited | 14.19 Million INR | -2362.194% |